<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Increasing experimental evidences suggest that ubiquitin-specific protease 22 (USP22), a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell marker, plays a crucial role in pathological processes of epithelial <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and other <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, which makes it a potential target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to study the roles of USP22 in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell line HCT116 by suppressing USP22 expression with micro-interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> (miRNA) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: With the knock-down of USP22, the changes of cellular proliferation, cell cycle, cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and major vault protein (MVP) expression were investigated </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> in <z:mp ids='MP_0003815'>nude</z:mp> mice was injected with USP22 miRNA silencing vector and the immunohistochemical staining was performed to evaluate the USP22 expression in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The knock-down of USP22 protein expression by miRNA resulted in the inhibition of cellular proliferation, the accumulation of cells in the G1 phase, the reduction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and the down-regulation of MVP expression </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, with orthotopic mice as a model, <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> was suppressed when USP22 miRNA silencing vector was injected </plain></SENT>
<SENT sid="6" pm="."><plain>Immunohistochemical analyses of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sections revealed that USP22 expression in animals decreased when USP22 expression was inhibited by miRNA </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: These results support the hypothesis that USP22 plays a crucial role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation and growth by regulating cell proliferation with USP22-dependent signaling pathway </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, USP22 acts as a major transcriptional factor to regulate MVP drug resistant gene </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, targeting USP22 may offer additional possibilities in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
</text></document>